We determined the relative contribution of Pl-and 2-adrenoceptor stimulation to the positive inotropic responses of human atrial myocardium to catecholamines. (-)Norepinephrine produced stimulation predominantly through f,-receptors and (-)epinephrine through both I31-and 2-receptors. However, there were marked differences in the responses of tissues from patients treated with the p31-selective antagonist atenolol compared with non-/-blocker-treated patients; surprisingly, f3-mediated responses were enhanced, and 3,1-mediated responses were unaltered. There was an enhanced responsiveness to (-)epinephrine (atenolol treated: -log M EC50, 7.57±0.07; non-,B-blocker treated: -log M EC50, 6.77±0.17; p<0.001), and the relative importance of P2-adrenoceptor stimulation was increased for both (-)norepinephrine and (-)epinephrine. In tissues from atenolol-treated patients, salbutamol, a p3-selective partial agonist, had an enhanced potency and a greater intrinsic activity (atenolol treated: -log M EC50, 7.13 ±0.09; intrinsic activity, 0.86±0.04; non-,-blocker treated: -log M EC50, 5.76+ 0.44; intrinsic activity, 0.39±0.13). We investigated possible mechanisms underlying the enhanced responsiveness to 12 stimulation. Determination of jB2-adrenoceptor affinity for salbutamol showed no change of affinity in atenolol-treated patients. Responses of the tissues to the cyclic AMP analogue dibutyryl cyclic AMP were not different between atenolol-treated and non- 
f3,ARs are situated on myocardial cells.12 In isolated strips of human myocardium, both atrium and ventricle, ,32AR stimulation causes positive inotropic effects. [11] [12] [13] [14] [15] [16] In vivo, stimulation of sinoatrial 832ARs causes a positive chronotropic effect. 17 The fact that myocardial 3,2ARs have functional roles in humans calls into question the appropriate use of 1,1-selective and nonselective 13-blockers in the treatment of cardiovascular diseases. To address this question we need to know the relative importance of f31AR and J32AR stimulation in the heart. It has already been shown that in isolated strips of ventricle (from patients without severe heart failure) 1, 2AR stimulation by endogenous catecholamines can achieve only 50% of the maximum 13AR-mediated inotropic response.'1 Our study was primarily designed to determine the relative contribution of f,1AR and 132AR stimulation to the effects of endogenous catecholamines on human atrium.
Initial results suggested that the inotropic 12
responsiveness is enhanced in tissues from patients treated with atenolol (a 1,-selective antagonist), while P, responsiveness is unchanged. 15 This was surprising because radioligand binding studies, using membrane preparations of right atrial myocardium, had shown an increased ,81AR density and an unchanged ,I2AR density in atenolol-treated patients compared with non-,B-blocker-treated patients. '8 One would therefore expect, in tissues from atenololtreated patients, an increased /3' responsiveness to inotropic stimulation by catecholamines rather than an enhanced /2 responsiveness.
Therefore, the second objective of our study was to investigate possible mechanisms underlying this unexpected increase in tissue sensitivity to f32AR stimulation. We examined two hypotheses: 1) We tested whether the enhanced 182 responsiveness was due to a selective increase in the affinity of p2ARs, which we measured using salbutamol. 19 2) We investigated whether the tissues from atenolol-treated patients had an enhanced responsiveness to positive inotropic stimuli that act distal to the 8ARs and adenylate cyclase, by using the cyclic AMP (cAMP) analogue dibutyryl cAMP (dbcAMP).20
Subjects and Methods Patients
Myocardial tissue was obtained from patients undergoing routine cardiac surgery at Papworth Hospital. Patients were having coronary artery bypass grafts, valve surgery, or both. Their degree of preoperative heart failure was classified according to New York Heart Association (NYHA) criteria, NYHA classes I, II, and III. NYHA class I heart failure is no dyspnea during ordinary physical activity, NYHA class II is dyspnea during ordinary physical activity, and NYHA class III is dyspnea during less than ordinary physical activity. None had been receiving PAR stimulants preoperatively. Patients receiving atenolol were taking 50 or 100 mg daily for more than 2 months, up to and including the day of operation.
Patients included in the initial experiments to determine the receptor subtype involvement in the responses to (-)epinephrine and (-)norepinephrine were divided into subgroups for further analysis according to prior drug treatment, NYHA classification, and disease state. For subsequent experiments patients were prospectively divided into two groups, those treated with atenolol and those not treated with p-blockers. Patients from these two groups were matched as closely as possible for age, gender, and NYHA status.
Preparation of Strips ofAtrial Myocardium
The right atrial appendage was excised immediately before the institution of cardiopulmonary bypass. Anesthesia was induced with midazolam and thiopentone, maintained with trichloroethylene and fentanyl with atracurium used as a muscle relaxant. Tissues were immediately placed in an oxygenated modified Na+ 125, K+ 5, Ca2+ 2.25, Mg2+ 0.5, Cl-98.5, S042-0.5, HCO3-32, HP042-1, and EDTA 0.04.
Dissection and setting up of the tissues was started within 45 minutes of surgical removal. Strips with a thickness <1 mm were prepared to facilitate diffusion of oxygen and drugs. Each atrial appendage yielded two to six strips. The tissues were mounted in a 50-ml organ bath21"22 at 370 C, containing a modified Krebs' solution as above supplemented with (mM) Na 15, fumarate 5, pyruvate 5, L-glutamate 5, and glucose 10 and constantly bubbled with 95% 02-5% CO2. Water for the solution was deionized and double glass distilled.
Atrial muscle strips were attached to strain-gauge transducers and driven at 2-second intervals with square-wave pulses of 5-msec duration and of just over threshold voltage. A length-force curve was determined, and the length was set at 40% of the length associated with maximum developed force (L,). Determination of a length-force curve for individual strips allowed us to use a standardized resting tension that takes account of the elasticity of each strip. A length of 40% Lm, was used rather than Lma because setting the length at Lmax would be associated with a continuous decay of resting tension throughout the experiment due to the elasticity of atrial strips. Also, the increases in force caused by catecholamines are larger at 40% Lm, than at LM. Because atrial appendages usually produced four strips (range, 2-6), responses were determined for either (-)epinephrine or (-)norepinephrine (only both when there were more than four strips). If there were fewer than four strips, the responses were determined in the following priority: with no blocker (+0), with either blocker (+ICI 118,551 or +CGP 20,712A), and then with both blockers (+ICI 118,551+CGP 20,712A).
Experiment 2: Onset and offset of blockade by atenolol. To determine the time of onset and offset of f3-blockade by (±)atenolol in our experimental tissues, we exposed atrial tissues of non-p-blockertreated patients to 600 nM (±)atenolol. We chose 600 nM because this is the expected plasma concentration in patients taking oral atenolol26 and because it is expected to cause a (-)norepinephrine concentration ratio of 15.16 Assuming that the slope of the concentration-effect curve for (-)norepinephrine is unchanged in the presence of atenolol, a concentration ratio of 15 would allow us to observe a residual stimulant effect of (-)norepinephrine in the presence of atenolol.
The experimental design was as in Reference 27. First, a concentration-effect curve to (-)norepinephrine was determined. From this a concentration of (-)norepinephrine was selected that produced 70% of the maximum response. The tissue was repeatedly exposed to this concentration of (-)norepinephrine, with washout of (-)norepinephrine between each exposure. The tissue was then exposed to 600 nM (±)atenolol, and the responses to (-)norepinephrine were repeated until equilibrium blockade was seen. The atenolol was then washed out with three changes of the bathing medium, and responses to (-)norepinephrine were again repeatedly determined until the responses had returned to a new equilibrium. The responses of a control strip not exposed to atenolol were also determined. This allowed us to measure the decline of the response seen with repeated exposure to (-) The equilibrium dissociation constant, Ks, for the salbutamol-/2AR complex was estimated from the comparison of the stimulant effects of salbutamol and (-)epinephrine and independently from the antagonism by salbutamol of the stimulant effects of (-)epinephrine. We compared the effects of (-)epinephrine (E) and salbutamol (S) by determining concentration-effect curves for the two Both methods use the assumption that there is a large 82AR reserve for (-)epinephrine, that is, that the maximum response to (-)epinephrine is produced by occupying only a small fraction of the receptor pool. 34 Experiment 4: Inotropic responses to dibutyryl cyclic AMP. To determine whether tissues from atenololtreated patients were more sensitive to inotropic stimuli acting at a level beyond the /3ARs and adenylate cyclase we examined the responses of tissues to dbcAMP. Cumulative concentration-effect curves were determined for dbcAMP for tissues from atenololtreated patients and non-p8-blocker-treated patients. The concentration-effect curves were followed by the addition of (-)isoproterenol (0.2 mM) to determine if maximum cAMP-mediated effects had been achieved. Then calcium chloride was added to raise the calcium concentration to 6.75 mM to determine if there was residual tissue responsiveness to calcium.
Statistics
All data were expressed as mean+SEM. Concentration-effect curves were constructed for individual strips for developed force expressed as a percent of isoproterenol, epinephrine, or salbutamol maximum. To determine agonist potencies and concentration ratios from the concentration-effect curves, concentrations were determined that produced 10%, 30%, Table 1 .
The resting tension of the atrial strips in non-pblocker-treated patients was 4.0+0.6 mN (mean+ SEM, n=22). Tissues from atenolol-treated patients had resting tensions of 3.3±0.4 mN (mean+SEM, n=30) (not significantly different). Developed force was also not significantly different between non-,p-blocker-treated patients and atenolol-treated patients. For non-,8-blocker-treated patients, n=22, basal force was 1.8+0.5 mN (mean±SEM) and maximal force (after isoproterenol) was 9.7±+1.4 mN (mean+SEM). For atenolol-treated patients, n=30, basal force was 1.6+0.5 mN (mean+SEM) and maximal force was 8.0±1.5 mN (mean+SEM).
CGP 20,712A and ICI 118,551 when producing blockade, whether given alone or together, caused parallel shifts of the concentration-effect curves to (-)epinephrine and (-)norepinephrine (Figures 1-3 ). Either antagonist given alone produced less blockade than when both were used together.
Experiment 1: ,-Adrenoceptor subtype involvement in catecholamine responses of non-,B-blocker-treated patients. There were 20 non-p-blocker-treated patients, 17 males and 3 females, aged 61±3 years (mean+SEM). Their NYHA status was: NYHA I, 9 patients; NYHA II or III, 11 patients.
In these patients the response to (-)epinephrine was not significantly antagonized by either p1AR blockade with CGP 20,712A or p82AR blockade with ICI 118,551 ( Figure 2 ). However, when both antagonists were used together they produced marked blockade (p<0.001) ( Figure 2 ). (Figures 1 and 3) .
The responses to (-)norepinephrine were antagonized by both J81AR blockade with CGP 20,712A (p<0.Ol) and f32AR blockade with ICI 118,551 (p<0.01) (Figure 3 ). Experiment 1: Effect of f1AR and f32AR stimulation on times to peak tension. Times to peak tension are shown in Table 2 . Both f31AR and /2AR stimulation cause a decrease in times to peak tension,p<0.001. The decrease in time to peak tension is similar for both (31AR and R2AR stimulation and is not influenced by prior atenolol therapy (no significant differences).
Experiment 1: Effect of other drug therapies and disease state on responsiveness to (-)epinephrine. Comparison of patients with NYHA I heart failure with those with NYHA II or III heart failure shows that responses to (-)epinephrine were not significantly affected by heart failure ( Table 3 ). The enhanced responsiveness to (-)epinephrine in atenolol-treated patients was still seen in patients grouped as having NYHA I heart failure alone or NYHA II or III heart failure alone.
Patients studied were on a range of medications. Calcium channel blockers have previously been reported to increase jBAR density.9 When our patients were divided into two groups according to whether or not they received calcium channel antagonists (nifedipine, verapamil, diltiazem, or nicardipine), no effect of these drugs was apparent on the responsiveness to (-)epinephrine. true when non-,B-blocker-treated patients were analyzed separately.
Other medications included nitrates (n= 12), diuretics (n=12), digoxin (n=7), warfarin (n=5), oral hypoglycemic agents (n=3), captopril (n=2), lipid-lowering agents (n=2), and nonsteroidal anti-inflammatory drugs (n=2).
Patients had coronary artery disease, valvular heart disease, or a mixture. When the comparisons of the response to (-)epinephrine between atenolol treated and non-p-blocker treated were confined to the subgroup of patients with coronary artery disease, the increased sensitivity to (-)epinephrine stimulation was still found. Relative to isoproterenol, salbutamol was a partial agonist. The intrinsic activity was greater in atenolol- Figure 7 . The estimated affinity of salbutamol for 832ARs, Ks, was similar for the two methods of determination and did not differ significantly between the two groups of patients (Table 4) .
In this group of experiments there were tissues from four non-,p-blocker-treated patients in which
Ua. (Table 4 ). The inotropic potency of salbutamol (-log M EC50) correlated with the intrinsic activity of salbutamol (r=0.89,p<0.001) (Figure 8 ). There was also a close correlation between salbutamol's intrinsic activity and the inotropic potency of (-)epinephrine (-log M EC50) (r=0.91,p<0.001) (Figure 8 effects, respectively, with no significant blockade of the ,lARs for which the antagonist has a low affinity.
In tissues from all patients, CGP 20,712A or ICI 118,551 alone caused much less than the expected blockade of the effects of (-)epinephrine and (-)norepinephrine with parallel shifts of the concentration-effect curves. When given together, the drugs produced approximately the expected degree of blockade of both (-)epinephrine and (-)norepinephrine. These findings indicate that the positive inotropic effects of both (-)epinephrine and (-)norepinephrine are produced through stimulation of l1ARs and fl2ARs and also that the maximum positive inotropic effects can be achieved through stimulation of either ,1AR or fl2AR subtypes with the second receptor being stimulated when the predominant receptor is blocked.
Within this overall pattern, the point of great interest was the different behavior of tissues from non-p-blocker-treated patients and atenolol-treated patients. In non-,8-blocker-treated patients the response to (-)epinephrine is not blocked by either CGP 20,712A or ICI 118,551 alone but blocked by 12.5*±5.2 Results are time to peak tension in milliseconds, mean+SEM. E+CGP, (-)epinephrine with 300 nM CGP 20,712A (atenolol treated, n= 11; non-fl-blocker treated, n= 11); NE+ICI, (-)norepinephrine with 50 nM ICI 118,551 (atenolol treated, n=10; non-fl-blocker treated, n=6); basal, before exposure to catecholamine; maximal, after exposure to catecholamine has produced the maximal increase in contractile force; decrease, difference in time to peak tension between basal and maximal. *p<0.001 (differences between basal and maximal). Decrease in time to peak tension is not significantly different between NE+ICI (fl1-adrenoceptors) and E+CGP (fl2-adrenoceptors) nor between atenolol-treated and nonfl-blocker-treated patients. (Figure 2 ). In atenolol-treated patients, the response to (-)epinephrine was blocked by ICI 118,551 but not by CGP 20,712A and hence was predominantly due to p2AR stimulation (Figures 1 and 3) . Compared with the responses of non-p-blocker-treated patients, this shows that the relative contribution of p2AR stimulation to (-)epinephrine's effects is increased. The response to (-)norepinephrine was blocked by both CGP 20,712A and ICI 118,551 alone and so was due to a mixture of 831AR and 82AR stimulation (Figure 3) . and one would predict that the several washing steps involved in the preparation of tissues before the determination of concentration-effect curves would remove all atenolol. The experiment determining the kinetics of the onset and offset rates of (±+)atenolol supports this conclusion with rapid onset and offset of blockade. Therefore, the responses of tissues from patients treated with atenolol are probably free from the influence of residual atenolol, and the selective increase in f32AR sensitivity is unlikely to be artifactual.
Could the differences in the responses to (-) groups of patients independent of the atenolol treatment? Previous studies have indicated that disease state, heart failure, and treatment with calcium channel blocking drugs can alter (3AR density and function.9,37-40 We examined our results taking these factors into account and found that they could not explain the increased responsiveness to (-)epinephrine in our patients (Table 3) . We also examined the effects of other drug treatment, age, and gender and found that these did not account for the differences seen. betes mellitus, chronic obstructive airways disease, aortic valve disease, heart failure, Raynaud's phenomenon, conduction tissue disease, intolerance of the medication, or physician preference. Such contraindications for (-blocker therapy were not absolute so that patients with these conditions were also represented in the atenolol-treated group. Obviously, a placebo-controlled prospective, randomized trial of the effects of atenolol on P3AR responsiveness would be needed to fully exclude all confounding variables. Unfortunately, such a study is not feasible in patients undergoing cardiac surgery, and therefore, it is probably impossible to examine so rigorously the effects of (3-blocker treatment on the responses of isolated human myocardium. We feel it is unlikely that such extraneous factors can account for the differences consistently found between atenolol-treated and non-/-blocker-treated patients. Our conclusion is that the differences in the responsiveness of the tissues to P2AR stimulation are due to a chronic effect of atenolol treatment.
What is the mechanism underlying this effect of atenolol? It would be unlikely that changes in receptor density alone could explain the increased sensitivity of tissues since the magnitude of the increased sensitivity to (32AR stimulation, almost 10-fold, would require a similar 10-fold increase in receptor density. Such extreme changes have never been previously reported. It is also unlikely that a change in receptor density even contributes to the increased sensitivity since radioligand binding studies of right atrial myocardium comparing tissue from atenololtreated patients with tissue from non-p-blockertreated patients have shown an increased ,81AR density and an unchanged (82AR density in atenololtreated patients.'8 These considerations led us to concentrate our experimental effort on alternative explanations. The selectively increased sensitivity to ,82AR stimulation could be due to either increased Hall et The salbutamol experiments were designed both to confirm the effect of atenolol on responsiveness to I32AR stimulation and to determine f2AR affinity. In human atrium, salbutamol's inotropic effect is due purely to I32AR stimulation (Figures 8 and 9 , Table 4 ). This is in contrast to the findings in other species since in cat right ventricular papillary muscle salbutamol is capable of inotropic stimulation through I31ARs.3 A possible explanation for this species discrepancy is that feline cardiac p1ARs are better coupled to inotropic effects than human cardiac 81ARs. 41 The affinity of salbutamol for /32ARs was determined by two different methods and found to be unaffected by prior atenolol treatment. The first method is dependent on salbutamol's stimulant action, and the second on salbutamol's ability to block the effect of (-)epinephrine on 832ARs. Both methods make the assumption that there are spare receptors for (-)epinephrine to produce positive inotropic effects, that is, that responses are maximal when only a small fraction of the receptors is occupied by epinephrine. Support for this assumption comes from membrane radioligand binding studies in which the affinity of (-)epinephrine is estimated to be 5.7-log M,41A42 whereas the EC50 for (-)epinephrine is 7.57-log M (in atenolol-treated patients) and 6.77-log M (in non-p-blocker-treated patients).
From this series of experiments we were also able to determine that the responses to salbutamol were enhanced in tissues from atenolol-treated patients compared with non-,B-blocker-treated patients. This part of the study was as close as practicable to a prospective case-control study, and again there was no discernible systematic bias in the physicians' pre- vious decision to use or avoid fl-blockade to explain the enhanced responsiveness of atenolol-treated patients. In the atenolol group salbutamol had a significantly higher intrinsic activity and lower EC50 (Table 4 ) with a close correlation between these two parameters ( Figure 8 ). There was also a close correlation between the intrinsic activity of salbutamol and sensitivity to (-)epinephrine (EC50) (Figure 8 ).
These correlations suggest that there is a common mechanism involved in the enhanced tissue respon- siveness to (-)epinephrine stimulation and the enhanced responsiveness to salbutamol. Since the affinity of salbutamol for the fl2ARs was unaltered in atenolol-treated patients, we suggest that the enhanced inotropic responses are due to an increased coupling of f82ARs to intermediary biochemical pathways. Support for this conclusion comes from analysis of the responses to salbutamol and (-)epinephrine in terms of the degree of receptor occupancy required to produce a given inotropic response. For atenolol-treated patients, the calculated receptor occupancy curve against agonist concentration is situated to the right of the curve for the inotropic effect against agonist concentration ( Figure   6 ). For non-,8-blocker-treated patients the curves for receptor occupancy and inotropic response are superimposed ( Figure 6 ).
Calculation of stimulant effect against receptor occupancy curves for both (-)epinephrine and salbutamol ( Figure 10 ) shows that the responses to both agonists are greater for a given degree of receptor occupancy in atenolol-treated patients than in nonfl-blocker-treated patients. The implication from this is that the signal resulting from occupation of each receptor by (-)epinephrine or salbutamol is greater in atenolol-treated patients. The relative efficacies of (-)epinephrine, eE, and salbutamol, es, can be estimated from comparisons of the receptor occupancies required to produce equal responses (Equation 7 ). Taking the efficacy of (-)epinephrine, eE, to be 1 (for both atenolol-treated and non-,8-blocker-treated patients) the mean (± SEM) calculated es from the curves in Figure 10 is 0.15 (+0.004) for atenololtreated patients and 0.14 (±+ 0.006) for non-,f-blocker-treated patients (not significantly different). The similarity of these two estimates of the relative efficacy of salbutamol compared with (-)epinephrine shows that the responses to the two agonists are enhanced to the same extent in atenololtreated patients. This sustains the argument that the enhanced responsiveness of tissues, from atenololtreated patients, to stimulation by salbutamol and (-)epinephrine is due to the same mechanisms.
At which level between receptor occupancy and increased contractile force could this amplification occur? There is evidence, in human myocardium, that both fl1AR and f82AR stimulation produce rises in cellular cAMP leading to activation of cAMPdependent protein kinase.35,43 dbcAMP is a stimulant that acts after the flARs and adenylate cyclase and before cAMP-dependent protein kinase activation. The tissues from atenolol-treated patients were shown not to be more sensitive to dbcAMP. This suggests that the alteration in sensitivity induced by atenolol treatment occurs at a point, in the chain of events linking occupation of a receptor by an agonist with increased contractile force, earlier than cAMPdependent protein kinase activation. However, we have recently reported a study of the chronotropic responses to intracoronary salbutamol in patients undergoing coronary angiography for the assessment of ischemic heart disease, most of whom were taking atenolol. 17 We found that salbutamol produced a sinus tachycardia by stimulating sinoatrial f32ARs. In one patient not taking atenolol there was a suggestion of a reduced responsiveness to salbutamol that would be in keeping with our in vitro findings. We are now seeking to confirm this finding in further clinical studies.
Are the concentrations of agonists used in our experiments physiologically relevant? Normal resting levels of (-)epinephrine are 0.25-1 nM, and at these concentrations threshold responses were observed in tissues from atenolol-treated patients. During stress much higher levels of (-)epinephrine have been found, for example, 30 nM in patients with myocardial infarction,48 which would produce responses in all our tissues in vitro. Plasma levels of salbutamol in patients may be up to 400 nM after oral therapy.49 Such a level is within our concentration-effect curves in vitro. Hence, the tachycardia seen in patients treated with salbutamol probably contains a component that is due to direct stimulation of myocardial /32ARs.
These considerations permit us, finally, to consider which therapeutic implications follow from our finding that atenolol treatment leads to increased f32AR coupling to inotropic effects. In patients with myocardial infarction the increased sensitivity to ,12AR stimulation may prove to be either beneficial or harmful. If one speculates that the same phenomenon that is occurring in atrium is also occurring in ventricle, then beneficial effects may include an increased inotropic effect to support the compromised pumping action of the heart. Deleterious effects could be due to a greater increase in heart rate and oxygen consumption of the heart thereby increasing the risks of arrhythmia and increasing the extent of infarction. It has been noted that oral salbutamol used to treat patients with heart failure has beneficial hemodynamic effects but has limited usefulness because of its adverse effect of provoking arrhythmia.50
If J32AR stimulation is generally deleterious in situations of high (-)epinephrine levels, then this suggests that patients with myocardial infarction or patients who are at risk of myocardial infarction would be better treated by nonselective 8-blockers rather than selective ,81AR blockade.
Another setting in which our findings may be of clinical relevance is in the treatment of patients with heart failure with p-blockers. In patients with heart failure due to congestive cardiomyopathy, treatment with the M,-selective antagonist metoprolol has been reported to be associated with beneficial hemodynamic effects.51-53 The mechanism underlying this has been assumed to be upregulation of f,BARs.40 However, a problem with accepting this assumption is that such upregulation would have to be to such an extent as to overcome the J31AR blocking effects of continu-ing metoprolol treatment. But, if the mechanism is analogous to our finding of increased sensitivity to ,f2AR stimulation after atenolol treatment, then the continued presence of 131AR blockade would not antagonize the increased responses to /32AR stimulation. Therefore, it is this increase in P2AR sensitivity and activity that may account for the beneficial hemodynamic effects of 131AR blockade in patients with heart failure. We have studied the responses to (-)epinephrine in four patients treated with metoprolol and found a -log M EC50 of 7.52±0.31 (not significantly different from our atenolol-treated group).
Conclusion
The human heart contains a higher proportion of /32ARs than other mammals. We have demonstrated that endogenous catecholamines can produce maximal effects through stimulation of I32ARs in human atrial myocardium and that the effect of (-)epinephrine is mediated through f31AR and /32AR stimulation. After treatment with the }31-selective antagonist atenolol the P2ARs are coupled better to production of inotropic effects and consequently have a more important role in the mediation of the effects of endogenous catecholamines.
